Type 2 diabetes is one of the most common metabolic diseases, affecting millions of people around the world. Its development is closely related to overweight, obesity, lack of physical activity and excessive caloric intake. Traditional treatment involves administering medications, including insulin, to help control blood glucose levels. However, even with appropriate pharmacotherapy, patients often struggle with the problem of excess energy, which is stored as fat, leading to further weight gain.
Swiss researchers from ETH Zurich have proposed a completely new approach to the fight against diabetes. Instead of influencing the way the body uses glucose, they decided to directly remove its excess from the blood using a special implant.
As the study authors emphasize:
"For decades we have treated diabetes by telling the body how to manage glucose. Now we show that we can directly control glucose levels using electronics, not drugs."
How does the implant work?
The key element of the device is an innovative catalyst that, under the influence of electricity, converts excess glucose into gluconate - a substance easily excreted from the body in urine. The catalyst is made of a graphite structure covered with gold nanoparticles and even smaller platinum particles. This advanced design enables effective and rapid glucose processing.
The device is equipped with an electronic control system enclosed in a 3D printed housing. The energy needed to operate the implant is supplied wirelessly, eliminating the need for frequent surgical interventions related to battery replacement. The system is also equipped with a sensor that monitors glucose levels, similar to those used by people with diabetes. The sensor constantly analyzes the sugar concentration in the fluid surrounding the cells and transmits the data to a smartphone or smartwatch via Bluetooth technology.
When the glucose level after a meal exceeds the set norm, the system automatically activates the implant. The process of converting glucose starts immediately, and when the desired sugar level is reached, the device turns off, preventing dangerous hypoglycemia.
Efficacy confirmed in studies on mice
The first tests were carried out in laboratory conditions, where the catalyst effectively converted glucose in a large volume of fluid, equivalent to the amount of blood in an adult human. The implant was then tested on diabetic mice. The results turned out to be very promising - the device allowed for precise control of glycemia, and a decrease in body weight was also observed in the animals.
The implant worked reliably for six weeks of testing and was well tolerated by the rodents. Importantly, no tissue damage caused by electricity or heat was noted, confirming the safety of the technology used.
Simple production and new perspectives in treatment
One of the advantages of the new solution is the lack of biological elements, such as living cells or enzymes, which are often difficult to produce and integrate with the patient's body. This allows the implant to be manufactured easier and faster, while remaining durable and safe.
According to prof. Martin Fussenegger, the main author of the study, this invention may open the way to the creation of completely new, electronically controlled therapies that can be integrated with digital health monitoring systems.
The future of therapy – preclinical research for now
Although the research results are very promising, scientists emphasize that the implant is still in the preclinical testing phase. No human trials have been conducted yet, so it is unknown whether the technology will be as effective and safe in patients.
However, the invention from ETH Zurich may revolutionize the treatment of type 2 diabetes, offering a new quality of life to millions of people around the world. If subsequent stages of research confirm their effectiveness and safety, these implants may soon become a common alternative to traditional pharmacological therapies.
